National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University MS 38677, USA.
National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University MS 38677, USA; Division of Pharmacognosy, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University MS 38677, USA.
Phytomedicine. 2024 Sep;132:155778. doi: 10.1016/j.phymed.2024.155778. Epub 2024 May 28.
Immulina®, a dietary supplement derived from Limnospira (formerly Arthrospira), is being investigated as a potential agent to increase antiviral resilience. In our recently published manuscript, we described the effects of Immulina® on influenza when taken daily, beginning before infection (prophylaxis) or after the onset of clinical symptoms of viral illness (therapeutic). However, the benefit of Immulina® in infected individuals before the manifestation of any symptoms (prodromal) has not been investigated yet.
To evaluate Immulina®'s potential use to increase the host antiviral immune response using a prodromal therapy regime.
The efficacy of Immulina® extract was evaluated in rodents using a prodromal protocol (test material administered prior to the emergence of viral illness symptoms).
Immulina® (25, 50 and 100 mg/kg body weight) was orally administered to both genders of mice, 2 h following influenza A viral infection, and continued daily for 14 days.
Compared to the infected control mice, animals fed Immulina® exhibited statistically significant reduction in the emergence of various physical symptoms of viral-induced illness and decreased viral RNA levels. The effects are likely mediated through the host immune system since the level of various cytokines (IL-6 and IFN-γ) were significantly increased in lung tissue.
This study, together with our previous paper, indicate that Immulina® was most effective at enhancing immune antiviral resilience if administered before or soon after initial infection. The data generated can be used to guide additional research using human subjects.
Immulina®是一种从 Limnospira（以前称为 Arthrospira）中提取的膳食补充剂，正在被研究作为一种增加抗病毒能力的潜在药物。在我们最近发表的一篇论文中，我们描述了 Immulina®在每天服用时对流感的影响，包括在感染前（预防）或出现病毒性疾病临床症状后（治疗）。然而，Immulina®在感染个体出现任何症状前（前驱期）的益处尚未得到研究。
评估 Immulina®在使用前驱期治疗方案时增加宿主抗病毒免疫反应的潜力。
使用前驱期方案（在出现病毒病症状之前给予测试材料）评估 Immulina®提取物在啮齿动物中的疗效。
在流感 A 病毒感染后 2 小时，给雌雄小鼠口服给予 Immulina®（25、50 和 100 mg/kg 体重），并持续 14 天每天给药。
与感染对照小鼠相比，给予 Immulina®的动物在出现各种病毒性疾病的身体症状和降低病毒 RNA 水平方面表现出统计学上的显著减少。这些效果可能是通过宿主免疫系统介导的，因为肺组织中各种细胞因子（IL-6 和 IFN-γ）的水平显著增加。
这项研究与我们之前的论文一起表明，Immulina®在感染初期或感染初期不久前给药时，增强免疫抗病毒能力的效果最佳。生成的数据可用于指导使用人类受试者的进一步研究。
